{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:10Z","timestamp":1790720350188,"version":"4.1.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>\n                    Approval of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE for the treatment of neuroendocrine tumors (NETs) requires monitoring for therapeutic efficacy and safety. A retrospective review was conducted on 173 patients who received\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE at the University of Michigan to identify if posology changes would improve therapy tolerance and completion. Patients were followed up to 3 years following their last cycle of treatment to determine long-term adverse events. Dose reduction (from 7.4\u00a0GBq to 3.7\u00a0GBq) was used in 13 patients, and cycle delay (8\u00b11\u00a0wk to &gt;16-week gap) was used in 36 patients, leading to 82% completion of 4 cycles of therapy. Dose reduction led to higher rates for completing all 4 cycles of therapy, whereas cycle delay led to worsened outcomes. Amino acid infusions led to limited adverse events with nausea, vomiting, and fatigue, even with antiemetic prophylaxis. Carcinoid crisis was observed in 1.2% of patients, which was similar to the findings in the NETTER-1 trial. Acute decline in neutrophils and platelets was observed; however, these blood values rebounded. A decline in renal function (4.3\u00a0mL\/min\/1.73\u00a0m\n                    <jats:sup>2<\/jats:sup>\n                    over 4 years compared with untreated patients) suggests a potential long-term risk for renal toxicity; however, it could also be associated with changes in therapy. When adverse events were severe due to underlying disease, dose reduction, or cycle delay did not adequately impact therapy completion, and required further therapy monitoring. Long-term occurrence of myelodysplasia syndrome was 1.8%, comparable to reported occurrences requiring further monitoring. Our analysis reinforces that\n                    <jats:sup>177<\/jats:sup>\n                    Lu-DOTATATE is an effective, well-tolerated treatment for NETs with low incidences of long-term adverse events.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006162","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:00:47Z","timestamp":1763125247000},"page":"1144-1151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Posology for 177Lu-DOTATATE Therapy in Neuroendocrine Tumor"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1318-9522","authenticated-orcid":false,"given":"Ivan E.","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan"},{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9492-1209","authenticated-orcid":false,"given":"Jasmine","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh","family":"Akhavanallaf","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-4988","authenticated-orcid":false,"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-1487","authenticated-orcid":false,"given":"Molly","family":"Roseland","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5580-5039","authenticated-orcid":false,"given":"Mitchel","family":"Muhleman","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk A.","family":"Frey","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0450","authenticated-orcid":false,"given":"Peter J. H.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Michigan"},{"name":"Department of Radiology, Division of Nuclear Medicine"},{"name":"Department of Pharmacology, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuni K.","family":"Dewaraja","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0837-7816","authenticated-orcid":false,"given":"Ka Kit","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Radiology, Division of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"5629","DOI":"10.2147\/CMAR.S174907","article-title":"Prognosis of patients with neuroendocrine tumor: a SEER database analysis","volume":"10","author":"Man","year":"2018","journal-title":"Cancer Manag Res"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"2042018818804698","DOI":"10.1177\/2042018818804698","article-title":"Current best practice in the management of neuroendocrine tumors","volume":"10","author":"Tsoli","year":"2018","journal-title":"Ther Adv Endocrinol Metab"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.3390\/cancers14215212","article-title":"Amino acid solutions for 177Lu-oxodotreotide premedication: a tolerance study","volume":"14","author":"Courault","year":"2022","journal-title":"Cancers"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00259-007-0691-z","article-title":"Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr 3]octreotate","volume":"35","author":"De Keizer","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000382053","article-title":"Clinical syndromes related to gastrointestinal neuroendocrine neoplasms","volume":"44","author":"Boutzios","year":"2015","journal-title":"Front Horm Res"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-011-2039-y","article-title":"Lutetium-labelled peptides for therapy of neuroendocrine tumours","volume":"39","author":"Kam","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/snuc.2002.31022","article-title":"Somatostatin receptor imaging","volume":"32","author":"Kwekkeboom","year":"2002","journal-title":"Semin Nucl Med WB Saunders"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R13-20251114","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"key":"R14-20251114","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ki.2012.443","article-title":"Change in the estimated glomerular filtration rate over time and risk of all-cause mortality","volume":"83","author":"Turin","year":"2013","journal-title":"Kidney Int"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"1393317","DOI":"10.3389\/fonc.2024.1393317","article-title":"Long-term clinical outcomes of [177Lu]Lu-DOTATATE in patients with metastatic neuroendocrine tumors","volume":"14","author":"Iqbal","year":"2024","journal-title":"Front Oncol Frontiers Media SA"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000493318","article-title":"Unmet needs in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)","volume":"108","author":"Sorbye","year":"2019","journal-title":"Neuroendocrinology"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/diagnostics11071216","article-title":"The dependence of renal 68Ga[Ga]-DOTATOC uptake on kidney function and its relevance for peptide receptor radionuclide therapy with 177Lu[Lu]-DOTATOC","volume":"11","author":"G\u00fchne","year":"2021","journal-title":"Diagnostics"},{"key":"R18-20251114","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s12630-012-9879-1","article-title":"Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review","volume":"60","author":"Seymour","year":"2013","journal-title":"Can J Anesth"},{"key":"R19-20251114","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13139-015-0332-6","article-title":"The challenges of treating paraganglioma patients with (177)Lu-DOTATATE PRRT: catecholamine crises, tumor lysis syndrome and the need for modification of treatment protocols","volume":"49","author":"Makis","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"R20-20251114","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/RLU.0000000000005375","article-title":"Improvement of laboratory hepatic parameters after treatment with 177 Lu-DOTATATE: cohort in an oncology reference center","volume":"49","author":"Dos Santos Soares","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R21-20251114","first-page":"e22392","article-title":"Lutetium-177 dotatate-induced hemolytic anemia and myelodysplastic syndrome","volume":"14","author":"Alkassis","year":"2022","journal-title":"Cureus"},{"key":"R22-20251114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-024-01077-7","article-title":"Risk of treatment-altering haematological toxicity and its dependence on bone marrow doses in peptide receptor radionuclide therapy","volume":"14","author":"Persson","year":"2024","journal-title":"EJNMMI Res"},{"key":"R23-20251114","doi-asserted-by":"crossref","first-page":"451","DOI":"10.7150\/thno.92487","article-title":"Long-term nephrotoxicity after PRRT: myth or reality","volume":"14","author":"Baum","year":"2024","journal-title":"Theranostics"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T13:00:51Z","timestamp":1763125251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000006162"}},"subtitle":["Effectiveness of Dose Reduction and Cycle Delay for Improving Therapy Tolerability"],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006162","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"2025-05-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}